Retail securitisation volume soars over two-fold to Rs 33,000 crore in Q1

The pandemic shocks had retail securitisation volumes plunging in the first quarters of the past two fiscal years, but the trend was reversed with the normalization of economic activities, pushing the securitisation volume by 113 percent in Q1 to Rs 33,000 crore from Rs 15,500 crore a year ago

PTI

August 01, 2022 / 22:42 IST

Representative image

With the economy normalizing to the pre-pandemic levels, credit off-take has been on an upswing and so does retail securitisation volume which soared more than two-fold to Rs 33,000 crore in the first quarter, shows an analysis.

The pandemic shocks had retail securitisation volumes plunging in the first quarters of the past two fiscal years, but the trend was reversed with the normalization of economic activities, pushing the securitisation volume by 113 percent in Q1 to Rs 33,000 crore from Rs 15,500 crore a year ago, according to an analysis by Care Ratings.

The retail securitisation volume includes pass through certificates (PTCs) and direct assignment (DA) transactions. Of the total, mortgage loans contributed around 47 percent of the DA transactions in Q1, while vehicle loan pools dominated the PTC volumes with 59 percent share.

The other major asset classes include microfinance loans (12 percent), gold loans (7.5 percent), and unsecured business loans, personal loans and consumer finance loans, cumulatively constituting 6.2 percent, says the report. The retail market volume was again driven by DA transactions, with 61 percent of the overall share, while the remaining share was of PTC deals.

The DA segment is led by mortgage-backed securitisation (MBS) with an aggregate size of around Rs 13,000 crore, followed by asset-backed securitisation (ABS) at around Rs 4,000 crore, which includes pools backed by all the asset classes (except mortgage loans and microfinance loans). MFI loans made up around 13 percent of the DA volume. PTC volume is mainly driven by ABS pools contributing around 73 percent of the total issuances and is led by vehicle loans at around Rs 7,600 crore accounting for around 59 percent.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show